Overview

Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)

Status:
Active, not recruiting

Trial end date:
2021-11-02

Target enrollment:

Participant gender:

Summary

The main aim of the study is to evaluate the efficacy, safety and impact on the health-related quality of life (HRQoL) in participants with moderate-to-severe chronic plaque psoriasis who are treated with tildrakizumab 100 milligrams (mg).

Phase:

Phase 4

Details

Lead Sponsor:

Almirall, S.A.

Treatments:

Antibodies, Monoclonal